“AMAG announced the commercial launch of Intrarosa (DHEA vaginal insert) as a treatment for moderate to severe dyspareunia associated with vulvar vaginal atrophy (VVA).”,” the firm’s analyst wrote.
AMAG has been the topic of several other reports. Zacks Investment Research raised AMAG Pharmaceuticals from a hold rating to a buy rating and set a $22.00 target price on the stock in a research note on Tuesday, July 11th. Jefferies Group LLC set a $40.00 target price on AMAG Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, April 20th. Deutsche Bank AG set a $24.00 target price on AMAG Pharmaceuticals and gave the stock a hold rating in a research note on Friday, July 7th. TheStreet cut AMAG Pharmaceuticals from a c rating to a d+ rating in a research note on Friday, May 5th. Finally, Barclays PLC reaffirmed an equal weight rating and set a $20.00 price objective (down from $25.00) on shares of AMAG Pharmaceuticals in a research report on Thursday, June 1st. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $28.09.
Shares of AMAG Pharmaceuticals (NASDAQ AMAG) traded up 1.18% during mid-day trading on Monday, hitting $17.15. The stock had a trading volume of 790,931 shares. The firm’s market cap is $605.19 million. The stock has a 50 day moving average price of $18.88 and a 200 day moving average price of $20.58. AMAG Pharmaceuticals has a 52 week low of $16.00 and a 52 week high of $36.83.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.18. The company had revenue of $158.39 million for the quarter, compared to analysts’ expectations of $158.83 million. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. AMAG Pharmaceuticals’s quarterly revenue was up 24.3% on a year-over-year basis. During the same period last year, the firm earned $1.45 earnings per share. Equities research analysts expect that AMAG Pharmaceuticals will post ($1.37) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Cantor Fitzgerald Reiterates Hold Rating for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)” was published by BNB Daily and is owned by of BNB Daily. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.baseball-news-blog.com/2017/08/19/amag-pharmaceuticals-inc-nasdaqamag-stock-rating-reaffirmed-by-cantor-fitzgerald-updated-updated-updated.html.
In related news, SVP Julie Krop sold 4,938 shares of the business’s stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $20.00, for a total value of $98,760.00. Following the completion of the transaction, the senior vice president now directly owns 28,336 shares in the company, valued at approximately $566,720. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.80% of the stock is owned by insiders.
A number of large investors have recently made changes to their positions in the stock. Sei Investments Co. raised its stake in shares of AMAG Pharmaceuticals by 0.7% in the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock worth $188,000 after buying an additional 54 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in shares of AMAG Pharmaceuticals by 1.4% in the first quarter. Louisiana State Employees Retirement System now owns 14,000 shares of the specialty pharmaceutical company’s stock worth $316,000 after buying an additional 200 shares in the last quarter. Arizona State Retirement System raised its stake in shares of AMAG Pharmaceuticals by 1.7% in the first quarter. Arizona State Retirement System now owns 17,900 shares of the specialty pharmaceutical company’s stock worth $404,000 after buying an additional 300 shares in the last quarter. Nordea Investment Management AB raised its stake in shares of AMAG Pharmaceuticals by 1.1% in the second quarter. Nordea Investment Management AB now owns 37,200 shares of the specialty pharmaceutical company’s stock worth $684,000 after buying an additional 400 shares in the last quarter. Finally, Teachers Advisors LLC raised its stake in shares of AMAG Pharmaceuticals by 0.7% in the second quarter. Teachers Advisors LLC now owns 62,481 shares of the specialty pharmaceutical company’s stock worth $1,150,000 after buying an additional 426 shares in the last quarter.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.